Detalhe da pesquisa
1.
Safety, tolerability, and efficacy of LiRIS 400 mg in women with interstitial cystitis/bladder pain syndrome with or without Hunner lesions.
Neurourol Urodyn
; 40(7): 1730-1739, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34288094
2.
The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
J Urol
; 198(1): 167-175, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28161352
3.
Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment.
J Urol
; 196(3): 801-8, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091236
4.
An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device.
J Endourol
; 37(1): 74-79, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36070450
5.
Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial.
Female Pelvic Med Reconstr Surg
; 27(7): 450-456, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32665528
6.
The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial.
Urology
; 153: 270-276, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33373708
7.
Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.
Neurology
; 91(7): e657-e665, 2018 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30030330